High-risk (HR) oncogenic mucosal human papillomavirus (HPV) types are the major cause of most carcinomas of the uterine cervix, as well as many other anogenital tumors, and are found in 20 to 30% of cancers of the head and neck (HNC) (36). While many HR HPVs share genomic organization and conserved sequence homologies, they vary significantly in their prevalences in vivo. HPV-16 is the most prevalent HR HPV, as it is present in nearly 50% of cervical and anogenital carcinomas and in more than 90% of HPV-associated HNC (15, 46) . In contrast, the sequence-related HPV-31 is significantly less prevalent than HPV-16 in cervical carcinomas and is rarely detected in HNC. Mechanisms determining HPV type-specific variations in viral persistence and malignant progression, however, are poorly understood.
High-risk (HR) oncogenic mucosal human papillomavirus (HPV) types are the major cause of most carcinomas of the uterine cervix, as well as many other anogenital tumors, and are found in 20 to 30% of cancers of the head and neck (HNC) (36) . While many HR HPVs share genomic organization and conserved sequence homologies, they vary significantly in their prevalences in vivo. HPV-16 is the most prevalent HR HPV, as it is present in nearly 50% of cervical and anogenital carcinomas and in more than 90% of HPV-associated HNC (15, 46) . In contrast, the sequence-related HPV-31 is significantly less prevalent than HPV-16 in cervical carcinomas and is rarely detected in HNC. Mechanisms determining HPV type-specific variations in viral persistence and malignant progression, however, are poorly understood.
Papillomaviruses (PVs) replicate as extrachromosomal double-stranded DNA plasmids after infection of the basal keratinocyte host, stably persisting in low copy numbers (10, 19, 25) . Early PV gene expression and plasmid amplification in the initial stages of HPV infection appear to be tightly regulated (18, 21, 30) through both transcriptional and posttranscriptional mechanisms (reviewed in references 43 and 60) . Both the E1 and E2 proteins are required for PV replication (6, 14, 18) , and as shown for HPV-31, transcripts encoding these factors from the plasmid genome are detected early after infection, followed by the production of mRNA encoding other early viral gene products (34) . This temporal, regulated expression of limiting levels of these transcription and replication modulators early in HPV infection suggests that these viral gene products are critical to the establishment phase of the viral life cycle. The precise mechanisms that limit HPV early gene expression or initial plasmid amplification and modulate the establishment of a stable viral copy number, however, have not been completely defined.
The full-length E2 and spliced E8 ∧ E2 isoforms are conserved in PVs, with E8 ∧ E2 transcripts identified in bovine papillomavirus type 1 (BPV-1) (26, 27) , HPV-11 (40) , cottontail rabbit papillomavirus (CRPV) (23) , HPV-31 (52) , and HPV-16 (11, 45) . As in BPV (1, 13, 16, 58) , E2 gene products expressed from a variety of HPVs modulate early gene transcription (5, 47, 48, 53, 56) and initial plasmid amplification (4, 21, 29, 35, 37) by distinct E2 structural domains, as shown in HPV-16 (41) and HPV-31 (51) . The HPV E2 protein isoforms exert their transcriptional and replication effects by interacting with defined cis binding sites which are also conserved in mucosal and cutaneous HPVs (42) as well as in animal PVs. E8 ∧ E2 interferes with E2-dependent transcriptional activation by the full-length E2 proteins via competitive binding to conserved E2 binding sites in BPV-1 (T. Haugen, unpublished data) and HPV-31 (54) . Similarly, HPV E8 ∧ E2 products can also inhibit plasmid replication (2, 61) . This study uses a newly developed complementation assay for HPV-16 replication to define the structure of the HPV-16 
MATERIALS AND METHODS
Plasmid constructions. Molecular cloning followed established protocols (9, 16, 17, 57) . Plasmid constructions are illustrated in the respective figures. The replication-competent HPV-16 strain W12E plasmid (GenBank accession no. AF125673) was a gift from P. Lambert (24) , while the HPV-31 plasmid was a gift from A. Lörincz (31) . All HPV-16 mutations were introduced into the HPV-16 W12E parent plasmid via PCR (22, 57) with the mutant oligonucleotides described below. The HPV-16 E1 precursor plasmid (a gift from the laboratory of H. zur Hausen), which contains a frameshift mutation by a single-base-pair deletion at position 1087 in the 3Ј portion of the E1 open reading frame (ORF) (12) , was excised with NcoI and BbsI and then cloned into the HPV-16 W12E plasmid. A similar E1 mutation was engineered into the HPV-31 E1 ORF. The HPV-16 E8 ORF mutation (E8Ϫ) alters the codon for W6 to a TAG termination codon with no change in the overlapping E1 ORF amino acid sequence. An identical W6-to-TAG mutation was engineered into the E8 ORF of the HPV-31 plasmid via BanII and SwaI digestion. The HPV-16 E2 DNA binding domain mutation (DBDϪ) is an XbaI termination linker that inserts a stop codon at nucleotide (nt) 3715 (E2 codon 321). The HPV-16 E2 TADϪ mutation is an XbaI termination linker at nt 2849 (E2 codon 32) that is outside the E1 and E4 ORFs. The pCG-neo plasmid was constructed using the BamHI-HindIII fragment from SV2-neo and the pCG backbone (57), while the pCG-(16)E2 and pE2x2tk-cat clones were cloned as described previously (16, 57) . The plasmid pCG T antigen (Tag) was constructed by inserting the simian virus 40 (SV40) large Tag ORF fragment, defined by the sequence comprising the BamHI site at nt 2533 up to a newly created XbaI site created upstream of the ATG at nt 5163 in the antisense strand of SV40, into the pCG vector backbone. The E2x3 SV40 enhancerless promoter SVE cat and SVE cat plasmids were described previously (16) . The SV2 tk (Ϫ38)-cat clones were generated by inserting a PCR fragment (nt 171 to 356 amplified from SV2 cat) containing both SV40 72-bp enhancer repeats into the polylinker of the ptk-cat constructions. All molecular constructions were verified by DNA sequencing.
The following synthetic oligonucleotide primers were used to introduce mutations into the HPV-16 W12E plasmid. The wild-type (wt) sequence is capitalized, while nucleotide substitutions are given in lowercase letters. Oligonucleotide positions in the HPV-16 genome are indicated (5Ј to 3Ј) in parentheses.
E8Ϫ (nt 1274 to 1293), CTGAAGTaGAAACTCAGCAG; E2 DBDϪ (nt 3539 to 3559), GCGCtcTAgAACCATGGTGGACAGTGCTCCAATCCTC; E2 TADϪ (nt 2840 to 2870), CATATAGtCTAgaGGAAACACATG CGCCTA; SA409Ϫ (nt 399 to 422), GTTAATTcGaTGTATTAACTGTC; SD880Ϫ (nt 863 to 891), CCATGGCTGATCCTGCAGGcACCAATGG; SD1302Ϫ (nt 1286 to 1315), CTCAGCAGATGTTACAGcTAGAAGGGCGCC; E2#1 mut (nt 30 to 66), GCGTAACCGAAATCGGTTGAgttGAAACCGGTTAGTA; E2#2 mut (nt 17 to 50), TATAAAACTAAGGGCGTAACCGAAATCtGTTGAA; E2#3 mut (nt 7850 to 7879), TGTGTGCAAAggGTTTTGGGTTACACATTT; E2#4 mut (nt 7850 to 7879), TATAAAcagccGGGCGTAACCGAAATCGGTTGAA; TATAA 65Ϫ (nt 45 to 75), GTTGAACCGAAACCGGTTAGT AgAgAcG CAG; Enhancer (Enh)Ϫ (nt 7670 to 7715), CTATGatCCAAgtCCTTAacaACC GCTGTTctGttgcgATTTTTGG. The following synthetic oligonucleotide primers were used to introduce mutations into the HPV-31 plasmid: E1Ϫ (nt 1027 to 1045), GTATACAACAATtAGGCAG; E8Ϫ (nt 1263 to 1284), CAATACTGA AGTaGAAACGCAG.
Cell culture and transcription assays. HeLa cell cultures were grown in Dulbecco's minimal essential medium with 7% iron-supplemented newborn calf serum and 1% fetal calf serum. HeLa cells, plated onto 150-mm dishes, were transfected in duplicate by calcium phosphate coprecipitation as described previously (9) . To assess transfection efficiency, cat plasmids driven by the SV40 promoter-enhancer or the murine sarcoma virus long terminal repeat were included as internal transfection controls. Enzymatic chloramphenicol acetyltransferase (CAT) assays and RNase protection assays were performed as described previously (9, 17) . "Primer walking" was performed by quantitative PCR using standard methods (see Fig. 5A ). 5Ј-end nested primers and a 3Ј-end reverse primer (nt 3529 to 3509) were used to PCR amplify (42 cycles) a synthetic DNA competimer (1 fg), spanning the 16-E8 ∧ E2 splice junction (nt 863 to 1302 and nt 3240 to 3835), and HPV-16 cDNA was derived from total RNA harvested from an HPV-16 wt/human foreskin keratinocyte (HFK) clonal cell line using RNAqueous kits (Ambion, Austin, TX). PCR products were resolved on a 1% agarose gel. Stock cultures of SCC13 cells (an HPV-negative squamous cell carcinoma line) (38) were grown on irradiated J2 fibroblast feeder cells in E media containing 0.5 g/ml hydrocortisone, 0.1 nM cholera toxin, 5 g/ml transferrin, 5 g/ml insulin, 2 nM 3,3Ј-5-triodo-L-thyronine, and 5 ng/ml epidermal growth factor (20) . For transient assays, SCC13 cultures were plated at a density of 2.4 ϫ 10 6 cells per 60-mm plate in the absence of irradiated feeder cells. Replication and immortalization assays. For transient-replication assays, HPV-16 W12E DNA constructs were first cleaved from pUC vector sequences with BamHI and then religated at 5 g/ml for 16 h. Ligated DNAs, reproducibly containing 30 to 50% of HPV sequences as single-copy plasmids, were purified over plasmid purification columns (maxikit; Qiagen, Valencia, CA), and 3 g was transfected into SCC13 cells with Effectene (Qiagen, Valencia, CA). Beta-galactosidase (␤-Gal) staining of control cultures transfected with pCMV-␤-Gal indicated transfection efficiencies of Ͼ50%. Cultures were split 1:2 at 24 h posttransfection and cultured for up to 5 days before total DNA harvesting (QIAamp DNA blood kit; Qiagen, Valencia, CA). DNA samples were quantified by optical density at 260 nm, digested with DpnI, and linearized with BamHI and XbaI before Southern blotting. The digestion of DNA samples was confirmed by visualization of ethidium bromide-stained agarose gels following electrophoresis. A total of 4 g of DpnI-resistant, whole-cell DNAs from transiently transfected SCC13 cultures was resolved on 1.0% agarose gels, depurinated in 0.25 M HCl, and blotted directly onto positively charged nylon membranes (Hybond-XL; Amersham Biosciences Corp., Piscataway, NJ) by alkaline transfer with 0.4 N NaOH. Aliquots of linearized HPV-16 W12E DNA (1 to 30 pg) were included as positive Southern blot controls and for normalizing the intensities of autoradiogram exposures. All blots included multiple replication-defective HPV-16 plasmids as negative blot controls that also served as DpnI digestion controls. Blots were then hybridized at 65°C with probes (1.5 ϫ 10 6 cpm/ml hybridization buffer) containing an equimolar cocktail of PCR-amplified segments of the HPV-16 W12E (nt 6226 to 3873 and nt 4471 to 6000) genome, [␣-32 P]dATP/dCTP labeled by random priming (HotPrime kit; GenHunter Corp., Nashville, TN).
For immortalization assays, 2 ϫ 10 6 primary HFK cells per 100-mm dish were transfected with 5 g HPV DNA and 1 g of RSV-neo. The cells were transferred via serial dilution onto three replicate plates containing irradiated J2 fibroblast feeders 1 day later, selected in 100 to 200 g G418/ml E medium for 5 days, and allowed to grow for another 10 to 20 days without selection. After the total colony numbers (ranging from 20 to 60 colonies per transfection) from replicate plates were determined, individual colonies were isolated using cloning cylinders and expanded from dishes with Ͻ40 colonies. Total DNA was harvested (as described above) from clonal cultures to determine HPV DNA status and plasmid copy number.
RESULTS

A 16-E8
∧ E2 spliced message encodes a repressor of early gene transcription. As in other cell lines containing extrachromosomal replicating plasmids of BPV-1 (7) (Fig. 1C) . In contrast to early gene expression from the native HPV promoters, constitutive 16-E8 ∧ E2 expression from the cytomegalovirus (CMV) promoter construct is not subject to feedback inhibition from E2 isoforms. Therefore, this CMV construct permits the examination of dose-dependent 16-E8 ∧ E2 effects in our transcription and replication assays. In transiently transfected HeLa cells, pCG (16)E8 ∧ E2 inhibited the transcription from a heterologous, E2-dependent CAT expression construct in a dose-dependent manner (Fig. 1D) .
To evaluate the ability of 16-E8 ∧ E2 to interfere with enhancer function, we used SV40 enhancer-driven cat constructions. When E2 binding sites were adjacent to the SV40 enhancer (either upstream or downstream), CAT expression was repressed with increasing amounts of pCG (16)E8 ∧ E2 ( Fig. 1E and 1F). In contrast, a construct without E2 binding sites was not inhibited (Fig. 1G ). These results demonstrate that 16-E8 ∧ E2 represses transcription in a dose-dependent manner presumably through a specific interaction with its cognate E2 binding site. The HPV-16 upstream regulatory region (URR) contains a cell type-dependent enhancer required for the activation of the P97 promoter by cellular transcription factors (8) . As seen with SV40 constructs, the addition of pCG (16) product in other HPVs has been described as an inhibitor of plasmid replication, we used 16-E8 ∧ E2-dependent inhibition of initial HPV-16 plasmid amplification (also referred to as "transient replication") as a measure of 16-E8 ∧ E2 expression.
SCC13 cells were transfected with full-length religated E8Ϫ mutant or wt HPV-16 plasmids ( Fig. 2A) . The amplification of wt HPV-16 is readily detected by Southern blotting DpnI/ BamHI-digested total DNA harvested 5 days after transfection ( Fig These results demonstrate that the initial HPV-16 plasmid amplification is repressed by a spliced viral gene product containing the E8 ORF.
In a parallel study (24a), the replication of an otherwise replication-defective plasmid, for example, one incapable of expressing E1, is rescued by adding a second plasmid species that expresses the missing replication factor in trans (e.g., the E1 gene product). The complementation of E1, which is essential for initial plasmid amplification, resulted in comparable amplifications of both plasmid species. Similarly, the transfection of an equimolar mixture of the wt HPV-16 plasmid expressing the E8 ORF (plasmid B) and the E8Ϫ mutant genome (defective for E8 expression; plasmid A) lowers the total replication of both plasmid species to levels similar to those produced by the wt alone ( Fig. 2A, lane 9 ). This observed repression via cotransfection of E8-expressing and E8-defective plasmid species constitutes our complementation assay that tracks E8-dependent inhibition of initial HPV-16 plasmid amplification ( Fig. 2A) . Cotransfection of the E8Ϫ plasmid with the E2 TADϪ plasmid also resulted in amplification levels similar to those of the wt plasmid. This indicates that the E2 TADϪ construct is still capable of expressing 16-E8 ∧ E2 in trans ( Fig. 2A, lane 10 ).
Since transfection with the DBDϪ mutant along with the E8Ϫ mutant permits increased plasmid amplification, it suggests that this negative factor is eliminated by a mutation in the DBD of E2 (Fig. 2A, lane 11 ). Simultaneous digestion with XbaI (which is a unique site within the DBDϪ or TADϪ constructs) yielded a different size for the DBDϪ fragment on Southern blots and showed that both the E8Ϫ and the E2 DBDϪ HPV-16 DNAs amplified to equivalent levels (data not shown). These results demonstrate that both the E8 and E2 DBD ORFs are required to inhibit initial HPV-16 plasmid amplification and are consistent with the expression of a 16-E8 ∧ E2 product.
In a cotransfection of the E8Ϫ plasmid with a plasmid containing a deletion of the major early gene promoter and adjacent ORFs (nt 7466 to 863), 16 ORF displayed three-to fourfold greater transcription than that of the wt in RNase protection assays (Fig. 3 , compare lane 1 to lanes 3, 4, 5, and 7). The increase in transcription, however, was not due to plasmid replication, as demonstrated by the E1-, E8-, and E2 DBDϪ constructs which are replication defective (Fig. 2, lanes 3 to 5) . Taken together, these data demonstrate that the defined 16-E8 ∧ E2 cistron generates an efficient repressor of early viral gene transcription that is independent of its inhibition of plasmid replication.
Regulation of 16-E8
∧ E2 expression. As noted for many HR HPVs, conserved cis elements within the noncoding URR are critical modulators of early gene expression (8, 22, 44, 59) . Although our deletion analysis showed that the major early promoter and adjacent ORFs were dispensable for 16-E8 ∧ E2-dependent inhibition of plasmid amplification ( Fig. 2A) , we wanted to determine whether conserved cis elements within the URR, which are critical for major early promoter regulation, contributed to the regulation of 16-E8 ∧ E2 expression. We modified our complementation assay (as depicted in Fig. 2 ) to determine whether discrete cis mutations in the HPV-16 coding and noncoding sequences influenced 16-E8 ∧ E2-dependent repression of initial plasmid amplification, independent of their effects on E1 or E2 expression, in transfected SCC13 cells by Southern blotting (Fig. 4) . As shown in Fig. 2 , the mutation of the 16-E8 ORF relieves the repression of HPV-16 plasmid amplification (Fig. 4 , plasmid A, lane 2), resulting in elevated plasmid levels compared to those of the wt (Fig. 4, lane 1) . The cotransfection of the E8-defective construct (plasmid A) with equimolar quantities of a second plasmid expressing 16-E8 ∧ E2, but not E1 or E2 (plasmid B, or E1-/E2 TAD-), results in restoration of 16-E8 ∧ E2-dependent repression, generating replication levels similar to those of the HPV-16 wt plasmid (Fig. 4 , compare lane 3 to lane 1). In contrast to our initial genetic complementations (Fig. 2) , cis mutations introduced into the E8 ∧ E2-expressing plasmid B in these refined complementation assays allowed us to gauge their effects on 16-E8 ∧ E2
expression by tracking 16-E8 ∧ E2-dependent repression of initial plasmid amplification, independent of any cis effects these mutations might also have on E1 or E2 expression. Consistent with our deletion analysis of the 16-E8 ∧ E2 cistron (Fig. 2, lane 12) , mutations in cis elements critical for E1 and E6/E7 expression did not abrogate 16-E8 ∧ E2-dependent activity. The mutation of the TATAA box at nt 65, T(65), which drives expression of the P97 major early promoter, had no effect on 16-E8 ∧ E2-dependent repression of plasmid amplification (Fig. 4, lane 5) . Similarly, the mutation of the splice acceptor site at nt 409, SA(409), which is required for E7 and E1 expression, had no significant effect on E8 ∧ E2-dependent inhibition (Fig. 4, lane 4) . The mutation of the keratinocyte-dependent enhancer (Fig.  4, lane 6) , the proximal E2 sites (sites 1 and 2) (Fig. 4, lane 7) , (Fig. 4, lane 8) , however, partially relieved 16-E8 ∧ E2-dependent inhibition of amplification, resulting in 5-to 6-fold repression compared to 11-to 15-fold repression with the unaltered E8 expressor construct (Fig. 4, lane 3 (Fig. 5A ). Primers capable of annealing to the spliced structure of 16-E8 ∧ E2 cDNA and the synthetic DNA competimer amplify both species with similar efficiencies. The competimer contains an additional 118 nt which can be discriminated from the cDNA product by gel electrophoresis. When both templates are present in the same PCR, the ratio of the two amplification products is the same as the template ratio in the initial reaction mixture and provides a measure of the mRNA amount in the original sample. Primers (with 5Ј ends, as in Fig. 5A at nt 1071, nt 1120, and nt 1142) amplified fragments from the competimer control (Fig. 5B, lanes 2, 7, and 11 ) with approximate mobilities of 540, 492, and 465 bp, respectively. Amplification of the cDNA alone generated fragments spanning the 1302 ∧ 3358 splice junction with approximate mobilities of 422, 374, and 347 bp (Fig. 5B,  lanes 4, 9, and 13 ). The ratio of the cDNA-competimer mixtures (Fig. 5B, lanes 3, 8, and 12 ) was quantified by scanning densitometry. The greater the ratio, the more cDNA was present in the original mixture. Since the cDNA aliquots were from the same mixture, the ratios of PCR products derived from one set of primers can be compared to those of another. The primer at nt 1126 to 1142 amplified 20-fold more cDNA than the primer at nt 1099 to 1029 and Ͼ100-fold more than the primer at nt 1051 to 1071 (Fig. 5B (Fig. 1H) , the E8 ∧ E2 of HPV-31 has also been shown to repress the replication of plasmids with heterologous origins when E2 binding sites are present in cis. We sought to determine whether 16-E8 ∧ E2 could similarly modulate viral replication by the direct repression of ori function, independent of its transcription repression function. We engineered a target plasmid that contained three E2 binding sites adjacent to the SV40 origin of replication (ori) (E2x3 SVE cat or E2-SV40) to quantify the ability of 16-E8 ∧ E2
to directly repress the replication of a heterologous ori driven by the large Tag of SV40. The consensus E2 binding site affinities in the SV40 construct are similar to the E2 binding site affinities in HPV-16 (57) . Increasing amounts of pCG (16)E8 ∧ E2 repressed the replication of E2-SV40 (Fig. 6B , lanes 2 to 5). In contrast, the replication of the SV40 ori plasmid lacking E2 sites was unaffected by the addition of 16-E8 ∧ E2 (Fig. 6B, lanes 7 to 10) . A construct expressing only
FIG. 4. cis elements regulate 16-E8
∧ E2 expression. Equimolar quantities of HPV-16 E8-defective (plasmid A) and E8-expressing (plasmid B) plasmid species were cotransfected into SCC13 cells as illustrated in the complementation scheme. Total DNA was harvested, and the total replication from both plasmid A and B species was monitored by Southern blotting after appropriate digestion. E1Ϫ, E8Ϫ, and E2 TADϪ indicate mutations in the respective genes, while SA409 refers to the indicated splice acceptor signal at nt 409. T(65) refers to mutation of the TATAA box at nt 65, enhϪ refers to the mutated keratinocyte-dependent enhancer, and E2#1ϩ2Ϫ (Fig. 6C, lane 4) . This result demonstrates that while physiologic levels of 16-E8 ∧ E2 can effectively repress initial HPV-16 plasmid amplification, they are not sufficient to repress E2-SV40 plasmid amplification. Since inhibition of replication from both plasmid species requires 16-E8 ∧ E2 expression and cis E2 sites ( Fig. 6A and B) , this suggests that the interactions of the 16-E8 ∧ E2 product with these sites are incomplete under these conditions. We conclude that 16-E8 ∧ E2-dependent repression of the SV40 replication occurs via a mechanism that is distinct from 16-E8 ∧ E2 repression of HPV-16 replication. We then examined the effects of 16-E8 ∧ E2 expression from its native promoter in trans on E1-dependent plasmid amplification in our refined complementation assays. As described in Fig. 4 , cotransfection of two plasmid constructs, which individ- ∧ E2 cDNA generated by competitive PCR, where "competimer" refers to the 1,052-bp PCR competitor DNA spanning the 16-E8 ∧ E2 splice junction and "M" represents a 100-bp ladder size marker. Arrows indicate approximate mobilities of cDNA relative to competimer products of various molecular weights. Representative amplification ratios (cDNA to competimer) were determined by scanning densitometry. (Fig. 6D, lane 2) . Endogenous expression of 16-E8 ∧ E2 (plasmid A) is sufficient to inhibit the amplification of both the E8-defective (plasmid B) and the E8-expressing (plasmid A) species (Fig. 6D, lane 2) . Mutation of the E8 ORF is sufficient to derepress plasmid amplification from both plasmids in this system (Fig. 6D, compare lanes 2 to 5) . The mutation of the proximal E2 binding sites (sites 1 and 2) in plasmid B (the source of E1) results in an increase in the amplification of plasmid A due to the increased expression of E1 in trans (Fig. 6D, compare lanes 2 and 3) . As we have shown in a parallel study (24a), mutation of the proximal E2 sites also impairs origin function in plasmid B (note the absence of the respective Dpn-resistant 5.4-kb band in Fig. 6D, lane 3) . As a control, the simultaneous mutation of the E1 ORF totally abolishes replication, confirming that our complementation assay monitors E1-dependent activity (Fig. 6D, lane 4) . In the absence of 16-E8 ∧ E2, mutation of the proximal E2 binding sites (which abrogate E2 binding in vitro [57] ) results in an even greater derepression (Fig. 6D, compare lanes 5 and 6) . This suggests that the E2-TA may also repress E1 expression. We conclude that physiologic levels of 16-E8 ∧ E2 are sufficient to repress expression of limiting levels of E1, resulting in inhibition of E1-dependent plasmid amplification.
16-E8
∧ E2 is not necessary for plasmid persistence and maintenance. We quantitatively compared the capacities of HPV-16 and HPV-31 wt and E8 mutant constructs to amplify initially after transfection into SCC13 cells (Fig. 7A) . Both the HPV-16 E8Ϫ and HPV-31 E8Ϫ constructs amplified 7.5-to 19-fold more efficiently than their respective wt constructs ( 3 and 8, respectively) . The HPV-31 and HPV-16 E1Ϫ constructs were included as replication-defective, negative controls (Fig. 7A, lanes 2 and 7) , while titrations of linearized HPV-16 and HPV-31 genomic fragments were used as quantitative controls (Fig. 7A, lanes 4, 5, 9 , and 10, respectively). These data demonstrate that the initial amplifications of both HPV-16 and HPV-31 (as previously reported [61] ) are similarly repressed by an E8 gene product. We then analyzed the capacities of the HPV-16 and HPV-31 wt and E8Ϫ mutant constructs to immortalize primary HFKs in three independent long-term transfections, using two distinct donor foreskins (Fig. 7B) . Interestingly, the HPV-16 E8Ϫ construct initially formed colonies after transfection into HFKs with an efficiency comparable to that of the HPV-16 wt genome. The HPV-31 E8Ϫ construct, however, was nearly threefold less efficient at initial HFK colony formation than the HPV-31 wt and, similar to mock (neo)-transfected keratinocytes, did not generate clonal cultures with extended life spans. Clonal cultures derived from primary HFKs transfected with either HPV-16 wt or E8Ϫ plasmids exhibited extended life spans (Ͼ30 population doublings) and stably replicating plasmids. The HPV-16 E8Ϫ cultures, however, were found to contain elevated extrachromosomal plasmid levels, with an average of 91 copies/cell versus 12 copies/cell with keratinocytes immortalized with the HPV-16 wt plasmid (Table 1) , as measured by Southern blotting (Fig. 7C) . This shows that 16-E8 ∧ E2 negatively modulates the HPV-16 copy number but is not required for plasmid maintenance in HPV-16-immortalized keratinocytes. Growth rates, expressed as population doublings in days, of the HPV-16 E8Ϫ/HFK clonal cultures (2.4 days) were distinct from those observed in HPV-16 wt/HFK clonal cultures (2.0 days) or uninfected primary keratinocytes (3.0 days) ( Table 1 ). These data confirm that, while both HPV-16 and HPV-31 wt and E8Ϫ mutant plasmids could initially amplify in transienttransfection assays, not all constructs were capable of successfully immortalizing primary keratinocytes. An HPV-31 plasmid with a similar mutation in the E8 ORF (in agreement with previous results [52] ) was not able to persist and extend the life spans of keratinocytes, as no persisting cultures harboring this plasmid construct were obtained. The HPV-16 E8 mutant genome, however, was able to persist as an extrachromosomal plasmid. also plays a role in the maintenance phase of the viral life cycle by limiting the levels of persistently replicating extrachromosomal HPV-16 plasmids. The E8Ϫ mutant of HPV-16 replicates at elevated levels compared to the HPV-16 wt, indicating loss of a replication inhibitor, but it reaches a stable plasmid copy number as opposed to the "runaway replication" observed in SV40 infection. Thus, complex mechanisms regulating persistent HPV replication appear to be distinct from those modulating the replication of other DNA tumor viruses (28, 55) . This HPV replication phenotype could reflect the exhaustion of limiting viral or cellular factors. Alternatively, HPV-16 replication could be modulated by an accumulation of other viral gene products which could antagonize replisome assembly of, for example, an E2-TA product or additional undefined HPV E2 isoforms. However, in contrast to BPV, where the robust expression of a truncated E2 transcription repressor (E2-TR) plays a critical role in viral transcription and replication, no evidence of transcripts capable of encoding an equivalent HPV-16 E2-TR isoform has been documented in the HPV-16 genome. In addition, mutation of putative ATG start sites within the E2 ORF, capable of encoding a potential 16-E2-TR gene product, resulted in no measurable effect on initial HPV-16 plasmid amplification (data not shown). construct, the nucleotide substitution within the 16-E8 ORF is identical to that described for the homologous HPV-31 E8 ORF mutation (61) , rendering this explanation inadequate to account for the disparate and reproducible phenotypes observed. Why does the HPV-16 E8Ϫ mutant generate clonal, immortalized HFK cultures with persistently replicating plasmids while the E8Ϫ mutant of HPV-31 does not? Perhaps it is due to the threefold-greater baseline plasmid amplification observed with the HPV-31 wt than with the HPV-16 wt (Fig. 7A) . The higher replication level of the HPV-31 E8Ϫ plasmid may be toxic to host cells and might exceed a critical threshold in the initial stages of the HPV life cycle, triggering potential host defenses to elevated viral DNA or an accumulation of viral polypeptides. The elevated HPV-16 E8Ϫ copy number observed in our clonal cultures, however, may not exceed this critical threshold, as it is stabilized at its new higher level, indicating that further increases in viral load are limited by an undetermined mechanism. Therefore, HPV type-specific modulation of viral load in the establishment phase of infection could play a role in the greater prevalence of HPV-16 in both asymptomatic infections and HPV-associated cancers.
DISCUSSION
There may also be additional, as yet unidentified, differences between the replication machineries of HPV-16 and HPV-31 that further modulate plasmid persistence. The disparity between E8
∧ E2 functions in HPV-16 and HPV-31 in the early stages of the HPV life cycle is consistent with observations that HR HPV types have evolved as unique viruses, with diverse properties determining their distinct pathogenicities and prevalences in HPV infection. These results underscore the need to independently examine the viral strategies of establishment and persistence of various HPV types.
